FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
PharmiWeb9d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
USA Today13d
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The drug, suzetrigine ... Journavx will be priced at $15.50 per pill. The FDA-approved medication, available as a 50-milligram prescription tablet taken every 12 hours, offers a non-opioid ...
USA Today14d
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
For the first time in two decades, the Food and Drug Administration (FDA) has approved ... 12 hours, according to a press release. The medication will be sold under the brand name Journavx for $ ...
Forbes23d
The Dangers Hidden In CMS’ Drug Pricing Regulation
one of the 15 drugs CMS has announced is subject to government price negotiation. Semaglutide was approved by the FDA in 2017 to treat type 2 diabetes. But the clinical benefits from the drug go ...
Business Wire22d
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted ... granted upon product approval. This important regulatory ...
Valneva Receives Marketing Authorization In The UK For The World’S First Chikungunya Vaccine, IXCHIQ®
February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
Medindia25d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Kelsey Warren KWarren6@its.jnj.com  609 218 4053 Investor contact: Lauren Johnson investor-relations@its.jnj.com ...
Gizmodo28d
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
It’s the active ingredient in type 2 diabetes drug Ozempic and the higher-dose obesity drug Wegovy. Since Wegovy’s FDA approval in 2021 ... have lost around 15% of their weight, well above ...